Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   30/04/2025
116,96 USD (+0,47%)
(+0,47%)   30/04/2025
Grafiek Jazz Pharmaceuticals plc Grafiek Jazz Pharmaceuticals plc
dinsdag 6 mei 2025, 22:00
Kwartaalcijfers (1ste kwartaal)

Jazz Pharmaceuticals plc in het nieuws

30 april 2025 · Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

25 april 2025 · Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer · Persbericht

23 april 2025 · Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma · Persbericht

22 april 2025 · Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 · Persbericht

21 april 2025 · Jazz Pharmaceuticals Completes Acquisition of Chimerix · Persbericht

26 maart 2025 · Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

19 maart 2025 · Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting · Persbericht

5 maart 2025 · Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio · Persbericht

9 september 2024 · Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 · Persbericht

5 september 2024 · Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

CEO: Bruce Cozadd

Werknemers: 3.199

Mijn selecties